Complications after BCG immunotherapy - neither a mountain nor a molehill Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment

Krajewski Wojciech; Poletajew Slawomir; Zdrojowy Romuald; Kolodziej Anna

首页> 外文期刊>Scandinavian journal of urology >Complications after BCG immunotherapy - neither a mountain nor a molehill Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment

【24h】

Complications after BCG immunotherapy - neither a mountain nor a molehill Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment

机译：BCG免疫疗法后的并发症 - 既不是山也不是Molehill Re：膀胱健康治疗BCG滴注治疗T1G2-G3膀胱癌 - 治疗开始后五年后的后续活动

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Scandinavian journal of urology》 |2019年第4期|共2页
作者
Krajewski Wojciech; Poletajew Slawomir; Zdrojowy Romuald; Kolodziej Anna;
展开▼
作者单位

Wroclaw Med Univ Dept Urol &

Oncol Urol Wroclaw Poland;

Med Univ Warsaw Dept Gen Oncol &

Funct Urol Warsaw Poland;

Wroclaw Med Univ Dept Urol &

Oncol Urol Wroclaw Poland;

Wroclaw Med Univ Dept Urol &

Oncol Urol Wroclaw Poland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Complications after BCG immunotherapy - neither a mountain nor a molehill Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment [J] . Krajewski Wojciech, Poletajew Slawomir, Zdrojowy Romuald, Scandinavian journal of urology . 2019,第4期

机译：BCG免疫疗法后的并发症 - 既不是山也不是Molehill Re：膀胱健康治疗BCG滴注治疗T1G2-G3膀胱癌 - 治疗开始后五年后的后续活动
2. Re: Long-Term Outcome of Patients with Frequently Recurrent Non-Muscle-Invasive Bladder Carcinoma Treated with One Perioperative plus Four Weekly Instillations of Mitomycin C followed by Monthly bacillus Calmette-Guerin ( BCG) or Alternating BCG and Interferon-alpha 2b Instillations: Prospective Randomised FinnBladder-4 Study [J] . Chang Sam S. The Journal of Urology . 2017,第3aPta1期

机译：Re：用一个围手术期加上四个每周霉菌菌素C的患者的长期结果常见的非肌肉侵入性膀胱癌，随后是每月芽孢菌植物霉素（BCG）或交替的BCG和干扰素-α2B滴注：前瞻性随机化的Finnbladder-4研究
3. Long-term Outcome of Patients with Frequently Recurrent Non-muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guerin (BCG) or Alternating BCG and Interferon-alpha 2b Instillations: Prospective Randomised FinnBladder-4 Study [J] . Jarvinen Riikka, Marttila Timo, Kaasinen Eero, European urology . 2015,第4期

机译：一次围手术期加丝裂霉素C每周四次滴注丝裂霉素-Cerin-Guerin（BCG）或交替BCG和干扰素-α2b滴注的围手术期加每周四次滴注治疗的复发性非肌肉侵犯性膀胱癌患者的长期结果：前瞻性随机FinnBladder -4学习
4. Optimal Control on Bladder Cancer Growth Model with BCG Immunotherapy and Chemotherapy [C] . C. Dewi, Trisilowati Symposium on Biomathematics . 2015

机译：BCG免疫疗法和化疗对膀胱癌生长模型的最佳控制
5. Understanding treatment-related symptoms, symptom management techniques, and symptom management self-efficacy in a sample of non-muscle invasive bladder cancer patients [D] . Hinojosa-Lindsey, Marilyn 2010

机译：了解非肌肉浸润性膀胱癌患者样本中与治疗相关的症状，症状管理技术和症状管理自我效能
6. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC a recombinant mycobacterium Bacillus Calmette Guérin (BCG) in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy [O] . Cyrill A. Rentsch, Piet Bosshard, Grégoire Mayor, 2020

机译：I期开放标签临床试验SAKK 06/14的结果评估了非肌肉浸润性膀胱癌和以前常规BCG治疗失败的患者中VPM1002BC重组分枝杆菌芽孢杆菌Guérin（BCG）膀胱内滴注的安全性
7. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy [O] . Cyrill A. Rentsch, Piet Bosshard, Grégoire Mayor, 2020

机译：I阶段开放标签临床试验SAKK 06/14评估VPM1002BC脑滴注的安全性，该重组分枝杆菌BacultusBudetteguérin（BCG），在非肌肉侵袭性膀胱癌患者中，以前的常规BCG治疗失败

Complications after BCG immunotherapy - neither a mountain nor a molehill Re: Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment

著录项

相似文献

相关主题

期刊订阅